AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8708654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin high dose (> 900 mg per day)
Number of subjects: 6171
Study 8708654 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 6171
Study 1424410 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg toloxatone three times a day
Number of subjects: 0
Study 1424410 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg toloxatone three times a day
Number of subjects: 0
Study 1424410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3936106 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (30‐90 mg per day)
Number of subjects: 31
Study 3936106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30291012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) arm (<120mmHg)
Number of subjects: 978
Study 30291012 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (SBP<140mmHg)
Number of subjects: 978
Study 30291012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive arm
Number of subjects: 978
Study 27718248 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CWMT
Number of subjects: 148
Study 27718248 — intervention group
Group type: COMPARATOR
Intervention: Nonadaptive/placebo version of CWMT
Number of subjects: 148
Study 27718248 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 148
Study 25398971 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH) plus recombinant LH (rLH)
Number of subjects: 579
Study 25398971 — intervention group
Group type: COMPARATOR
Intervention: Highly purified hMG (HP-hMG)
Number of subjects: 579
Study 24414382 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist position at 45°
Number of subjects: 100
Study 24414382 — intervention group
Group type: COMPARATOR
Intervention: Wrist position at 0°
Number of subjects: 100
Study 24414382 — intervention group
Group type: COMPARATOR
Intervention: Wrist position at 15°
Number of subjects: 100
Study 24414382 — intervention group
Group type: COMPARATOR
Intervention: Wrist position at 30°
Number of subjects: 100
Study 24414382 — intervention group
Group type: COMPARATOR
Intervention: Wrist position at 60°
Number of subjects: 100
Study 21920062 — intervention group
Group type: EXPERIMENTAL
Intervention: High-soya diet for 6 months
Number of subjects: 79
Study 21920062 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-soya diet for 6 months
Number of subjects: 79
Study 21920062 — intervention group
Group type: EXPERIMENTAL
Intervention: High-soya diet
Number of subjects: 79
Study 21920062 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-soya diet
Number of subjects: 79
Study 21920062 — intervention group
Group type: COMPARATOR
Intervention: Comparison between high-soya and low-soya diets
Number of subjects: 79
Study 19530004 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fetal pulse oximetry (FPO) plus fetal heart rate (FHR) monitoring
Number of subjects: 230
Study 19530004 — intervention group
Group type: COMPARATOR
Intervention: FHR monitoring alone (Control)
Number of subjects: 230
Study 18158708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg/day
Number of subjects: 16
Study 18158708 — intervention group
Group type: COMPARATOR
Intervention: Control (no ACE inhibitor)
Number of subjects: 16
Study 15122049 — intervention group
Group type: EXPERIMENTAL
Intervention: Typbar
Number of subjects: 184
Study 15122049 — intervention group
Group type: COMPARATOR
Intervention: Vaccine 'X'
Number of subjects: 184
Study 11808977 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary iPF2alpha‐III concentrations in patients with Crohn's disease
Number of subjects: 23
Study 11808977 — intervention group
Group type: COMPARATOR
Intervention: Urinary iPF2alpha‐III concentrations in healthy controls
Number of subjects: 23
Study 11808977 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary iPF2alpha‐III concentrations in patients with clinical relapse
Number of subjects: 23
Study 11808977 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary iPF2alpha‐III concentrations in patients with clinical remission
Number of subjects: 23
Study 11808977 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between urinary iPF2alpha‐III and plasma C-reactive protein concentrations
Number of subjects: 23
Study 10024259 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg or 20 mg daily for 2 weeks
Number of subjects: 677
Study 10024259 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily for 2 weeks
Number of subjects: 677
Study 10024259 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 677
Study 10024259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment overall
Number of subjects: 677
Study 7580003 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot leuprorelin (3.75 mg IM injection)
Number of subjects: 117
Study 7580003 — intervention group
Group type: COMPARATOR
Intervention: Daily buserelin (0.3 mg SC twice daily)
Number of subjects: 117
Study 2134562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine intermittent infusion (300 mg every 8 hours)
Number of subjects: 27
Study 2134562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine intermittent infusion (300 mg every 6 hours)
Number of subjects: 27
Study 2134562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine continuous infusion (600 mg per day)
Number of subjects: 27
Study 2134562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine continuous infusion (900 mg per day)
Number of subjects: 27
Study 2134562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine continuous infusion (1200 mg per day)
Number of subjects: 27
Study 6159711 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 2 months followed by thiacetazone plus isoniazid for 6 months
Number of subjects: 0
Study 6159711 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 2 months followed by thiacetazone plus isoniazid for 8 months
Number of subjects: 0
Study 6159711 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 1 month followed by thiacetazone plus isoniazid for 6 months
Number of subjects: 0
Study 6159711 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug regimen (streptomycin, isoniazid, rifampicin, pyrazinamide) for 1 month followed by twice-weekly streptomycin, isoniazid and pyrazinamide for 6 months
Number of subjects: 0
Study 6159711 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-drug regimen without pyrazinamide for 2 months followed by thiacetazone plus isoniazid for 6 months
Number of subjects: 0
Study 6140492 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg twice a day for seven days
Number of subjects: 40
Study 6140492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6140492 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2 g dose of metronidazole after placebo failure
Number of subjects: 40
Study 6140492 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of infection after treatment
Number of subjects: 40
Study 6140492 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical findings
Number of subjects: 40
Study 30045174 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional imaging with computer simulation (n = 10)
Number of subjects: 100
Study 30045174 — intervention group
Group type: COMPARATOR
Intervention: Tissue-based planning without simulation (n = 13)
Number of subjects: 100
Study 30045174 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall breast augmentation (both groups)
Number of subjects: 100
Study 26219549 — intervention group
Group type: EXPERIMENTAL
Intervention: Face Mask (FM) therapy with a force of 400g for each side
Number of subjects: 50
Study 26219549 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletal Anchorage (SA) therapy with intermaxillary elastics and a force of 200g
Number of subjects: 50
Study 24859491 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (450 mg/day)
Number of subjects: 35
Study 24859491 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (150 mg/day)
Number of subjects: 35
Study 24859491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 22313027 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (individualized counselling aimed at reducing weight and increasing physical activity)
Number of subjects: 522
Study 22313027 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 522
Study 20399994 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg
Number of subjects: 36
Study 20399994 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 36
Study 20399994 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 36
Study 20399994 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg (steady state)
Number of subjects: 36
Study 20399994 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg (steady state)
Number of subjects: 36
Study 20399994 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg (steady state)
Number of subjects: 36
Study 19298033 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional nonnavigated instrumentation
Number of subjects: 0
Study 19298033 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional, open navigated instrumentation
Number of subjects: 0
Study 19298033 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive navigated experimental instrumentation
Number of subjects: 0
Study 19298033 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive navigation-dedicated instrumentation
Number of subjects: 0
Study 15003431 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone-IR
Number of subjects: 70
Study 15003431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 11285968 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Number of subjects: 110
Study 11285968 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 110
Study 9135508 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin 35 mg/m2 day 1 and prednimustine 100 mg/m2 days 2-6, every 21 days
Number of subjects: 19
Study 9135508 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin 15 mg/m2 days 1, 2 and 3 and prednimustine 100 mg/m2 days 2-6, every 21 days
Number of subjects: 19
Study 7534946 — intervention group
Group type: EXPERIMENTAL
Intervention: Saruplase (20 mg bolus plus 60 mg continuous 1 h i.v. infusion)
Number of subjects: 12
Study 3556262 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound analgesic/anti-emetic formulation (paracetamol 500 mg, codeine phosphate 8 mg, buclizine hydrochloride 6.25 mg, dioctyl sodium sulphosuccinate 10 mg) taken as two tablets during acute attack
Number of subjects: 34
Study 3556262 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 34
Study 29857919 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of rosuvastatin (5, 10, and 20 mg) with ezetimibe (10 mg)
Number of subjects: 0
Study 29857919 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin monotherapy (5, 10, and 20 mg)
Number of subjects: 0
Study 26709942 — intervention group
Group type: COMPARATOR
Intervention: PBSS (control group A)
Number of subjects: 54
Study 26709942 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-live virus vaccines (groups B, C, D, E)
Number of subjects: 54
Study 24410993 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 45
Study 24410993 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg caffeine
Number of subjects: 45
Study 24410993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 22867111 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU compounded vitamin D3 capsule monthly)
Number of subjects: 400
Study 22867111 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical inert capsule)
Number of subjects: 400
Study 20302407 — intervention group
Group type: EXPERIMENTAL
Intervention: Levator resection
Number of subjects: 20
Study 20302407 — intervention group
Group type: EXPERIMENTAL
Intervention: Levator plication
Number of subjects: 20
Study 17574729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER (2mg once daily) for 12 months
Number of subjects: 318
Study 17574729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 15591735 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch toothpick with AmF
Number of subjects: 15
Study 15591735 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch toothpick with NaF
Number of subjects: 15
Study 15591735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental floss with AmF + NaF
Number of subjects: 15
Study 15591735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental floss without F
Number of subjects: 15
Study 15591735 — intervention group
Group type: COMPARATOR
Intervention: Control period without any approximal cleaning
Number of subjects: 15
Study 15591735 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF toothpick
Number of subjects: 15
Study 15591735 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF toothpick
Number of subjects: 15
Study 12188594 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-Step Facilitation (TSF)
Number of subjects: 133
Study 12188594 — intervention group
Group type: COMPARATOR
Intervention: Structured Relapse Prevention (RP)
Number of subjects: 133
Study 12188594 — intervention group
Group type: EXPERIMENTAL
Intervention: Random assignment to aftercare consistent with participant preference
Number of subjects: 133
Study 9831971 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 70
Study 8076917 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg acetylsalicylic acid/day
Number of subjects: 44
Study 8076917 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 2692264 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and ampicillin treatment for one to four days, wounds closed on the fourth day.
Number of subjects: 0
Study 4936439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine
Number of subjects: 82
Study 4936439 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 30898323 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual female-specific cognitive behavioral therapy (I-FS-CBT)
Number of subjects: 155
Study 30898323 — intervention group
Group type: COMPARATOR
Intervention: Group female-specific cognitive behavioral therapy (G-FS-CBT)
Number of subjects: 155
Study 28977019 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid chart and a cup (200ml)
Number of subjects: 138
Study 26912161 — intervention group
Group type: EXPERIMENTAL
Intervention: α-linolenic acid (ALA) treatment (4.0 g daily for 12 weeks)
Number of subjects: 26
Study 26912161 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 26
Study 25432827 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy (RARP)
Number of subjects: 148
Study 25432827 — intervention group
Group type: COMPARATOR
Intervention: Open retropubic radical prostatectomy (ORRP)
Number of subjects: 148
Study 25432827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical prostatectomy
Number of subjects: 148
Study 22151299 — intervention group
Group type: EXPERIMENTAL
Intervention: Training administered to working mothers on breastfeeding techniques, duration: five home visits starting two weeks before returning to work until infants are six months old.
Number of subjects: 0
Study 22151299 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained mothers)
Number of subjects: 0
Study 19219236 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified rice for 16 weeks
Number of subjects: 354
Study 19219236 — intervention group
Group type: COMPARATOR
Intervention: Placebo rice for 16 weeks
Number of subjects: 354
Study 19219236 — intervention group
Group type: EXPERIMENTAL
Intervention: Total iron intake of 53.76mg from fortified rice
Number of subjects: 354
Study 17649720 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA + As4S4 + chemotherapy
Number of subjects: 60
Study 17649720 — intervention group
Group type: COMPARATOR
Intervention: ATRA + chemotherapy
Number of subjects: 60
Study 14997024 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 36
Study 14997024 — intervention group
Group type: COMPARATOR
Intervention: Standard parenteral nutrition protocols
Number of subjects: 36
Study 11595001 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 1385
Study 11595001 — intervention group
Group type: COMPARATOR
Intervention: Tension-type headache
Number of subjects: 1385
Study 10664935 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood IgE levels in infants with obvious atopic disease
Number of subjects: 114
Study 10664935 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE levels at 12 months in infants with obvious atopy
Number of subjects: 114
Study 10664935 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE levels in relation to male sex
Number of subjects: 114
Study 10664935 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE levels in relation to black race
Number of subjects: 114
Study 10664935 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE levels in relation to breast-feeding duration
Number of subjects: 114
Study 10664935 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE levels in relation to family income
Number of subjects: 114
Study 7868711 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole daily
Number of subjects: 30
Study 7868711 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole twice daily
Number of subjects: 30
Study 7868711 — intervention group
Group type: COMPARATOR
Intervention: 250 mg/day terbinafine
Number of subjects: 30
Study 7868711 — intervention group
Group type: COMPARATOR
Intervention: 200 mg/day itraconazole
Number of subjects: 30
Study 2220995 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program using a handout as the only educational tool
Number of subjects: 18
Study 2220995 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program using a handout and a hands-on demonstration
Number of subjects: 18
Study 2220995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 18
Study 326100 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable laminar air-flow filter (Enviracaire)
Number of subjects: 13
Study 326100 — intervention group
Group type: COMPARATOR
Intervention: Control (no filter)
Number of subjects: 13
Study 31128221 — intervention group
Group type: EXPERIMENTAL
Intervention: Approaches using post-randomized controlled trial data
Number of subjects: 0
Study 31128221 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified approach using post-trial data from participants taking the drug after trial
Number of subjects: 0
Study 31128221 — intervention group
Group type: COMPARATOR
Intervention: Combined initial trial and post-trial follow-up data
Number of subjects: 0
Study 27436028 — intervention group
Group type: EXPERIMENTAL
Intervention: Particulate steroids
Number of subjects: 531
Study 27436028 — intervention group
Group type: COMPARATOR
Intervention: Non-particulate steroids
Number of subjects: 531
Study 25811109 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamine (25 g)
Number of subjects: 10
Study 25811109 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole protein (25 g)
Number of subjects: 10
Study 25811109 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 24014905 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (15 mg single oral dose)
Number of subjects: 12
Study 24014905 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 12
Study 22336008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster schedule (6-week duration)
Number of subjects: 80
Study 22336008 — intervention group
Group type: COMPARATOR
Intervention: Conventional schedule (14-week duration)
Number of subjects: 80
Study 22336008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster schedule
Number of subjects: 80
Study 22336008 — intervention group
Group type: COMPARATOR
Intervention: Conventional schedule
Number of subjects: 80
Study 22336008 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 80
Study 19152871 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 348
Study 19152871 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 348
Study 19152871 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 348
Study 17224599 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 120
Study 17224599 — intervention group
Group type: COMPARATOR
Intervention: Invasive needle control
Number of subjects: 120
Study 17224599 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 15153172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg once daily
Number of subjects: 893
Study 15153172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 800 mg once daily
Number of subjects: 893
Study 15153172 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 800 mg three times daily
Number of subjects: 893
Study 15153172 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 893
Study 11533321 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for clinicians and parents
Number of subjects: 1136
Study 11533321 — intervention group
Group type: COMPARATOR
Intervention: Control region (no educational intervention)
Number of subjects: 1136
Study 9791684 — intervention group
Group type: EXPERIMENTAL
Intervention: Remantadine (1.5 mg/kg body weight 3 times a day for 3 days)
Number of subjects: 802